No Data
Heung Yu-B (02256.HK) spent 0.94 million HKD on March 11 to repurchase 0.122 million shares.
Gelonghui reported on March 11 that He Yu-B (02256.HK) announced the repurchase of 0.122 million shares at a cost of 0.94 million Hong Kong dollars on March 11.
Hong Kong stocks fluctuated | Hoyu-B (02256) rose more than 5% during the session. Institutions indicate that the company is expected to see a busy harvest this year, and currently has abundant Cash / Money Market.
He Yu-B (02256) rose over 5% during the trading session, as of the time of this report, it is up 5.43%, priced at 7.76 Hong Kong dollars, with a transaction volume of 11.6791 million Hong Kong dollars.
Harmony and Praise-B (02256.HK) spent 2.207 million Hong Kong dollars to repurchase 0.3 million shares on March 10.
Gelonghui March 10丨He Yu-B (02256.HK) announced that on March 10, it spent 2.207 million Hong Kong dollars to repurchase 0.3 million shares.
He Yu-B: The IND application for the new PRMT5*MTA inhibitor ABSK131 has been approved by the China CDE.
Heyu-B (02256) issued an announcement that on March 6, 2025, Shanghai Heyu Biomedical Technology Co., Ltd. announced today that the clinical research application for the highly selective small molecule PRMT5*MTA inhibitor ABSK131 has been approved by the Drug Evaluation Center of the National Medical Products Administration of China. The IND application was approved by the FDA in the USA in early December 2024. A Phase I clinical study will be conducted in patients with advanced solid tumors, named "A Phase I study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABSK131 in patients with advanced/metastatic solid tumors."
Abbisko Cayman Limited Beat Analyst Profit Forecasts, And Analysts Have New Estimates
He Yu-B (02256.HK): The IND application for the new PRMT5*MTA inhibitor ABSK131 has been approved by China's CDE.
Gelonghui, March 6丨He Yu-B (02256.HK) announced that its subsidiary Shanghai He Yu Biomedical Technology Co., Ltd. ("He Yu Pharmaceutical") today announced that the clinical research application for the highly selective small molecule PRMT5*MTA inhibitor ABSK131 has been approved by the Drug Evaluation Center of the National Medical Products Administration of China. Its IND application was approved by the FDA of the USA in early December 2024. This is a voluntary announcement issued by the company. The group cannot guarantee that ABSK131 will ultimately be successfully approved for marketing. Shareholders of the company and potential investors are advised to act with caution when trading company shares.
